Siegfried : Management Changes
Siegfried Group (Zofingen) has announced two management changes. Chief Financial Officer (CFO) Michael Hüsler will be leaving the company at the end of April 2017 to take up a new professional challenge. Michael Hüsler has been CFO and a member of the firm's Executive Committee since 2009. The Board of Directors has appointed Dr. Reto Suter, formerly CFO and Chief Investment Officer at Lonrho, as his successor. Reto Suter will take over the reins on May 1, 2017.
Says CEO Dr. Rudolf Hanko: 'Michael Hüsler led the Finance department successfully and was instrumental in shaping and supporting our company's expansion. He made a major personal contribution to Siegfried's overall success during his tenure. We have found a highly experienced and competent successor to Michael Hüsler in Dr. Reto Suter.'
Likewise with effect from May 1, 2017, the Board of Directors has entrusted Dr. Wolfgang Wienand with the management of the Siegfried Group's global research and development activities. He will be taking over these duties from Dr. René Imwinkelried and will perform this function in addition to his existing responsibilities as Head Strategy, M&A, Legal, IP and Regulatory Affairs. René Imwinkelried continues to manage the Global Technical Operations department - a role he has held since the beginning of the year.
As per May 1, 2017, the members of the Executive Committee are as follows:
- Dr. Rudolf Hanko, CEO
Dr. Wolfgang Wienand, Head of Research and Development,
Head Strategy and M&A, Legal, IP, Regulatory Affairs
- Dr. René Imwinkelried, Head of Global Operations
- Dr. Reto Suter, CFO
- Marianne Späne, Head Business Development & Sales
- Arnoud Middel, Head Human Resources Global
CV Dr. Reto Suter
Reto Suter studied economics at the University of Zurich and the University of Washington in Seattle and took his doctorate in banking and finance at the University of Zurich. Over the last 16 years, he has held a range of responsible positions in industry as well as in finance and private equity. In his last post as CEO, CIO and Board Member, Reto Suter was responsible for overseeing the public takeover and subsequent delisting and restructuring of Lonrho, a long-established company headquartered in London (UK) and Johannesburg (SA).
CV Dr. Wolfgang Wienand
Wolfgang Wienand studied chemistry at the Friedrich-Wilhelms University in Bonn and received his Ph.D. from the University of Cologne, Germany. He also holds an Executive Master Degree in International Finance from HEC Paris.
Wolfgang Wienand joined Siegfried in 2010. In his capacity as Chief Scientific Officer and member of the Executive Committee, he was initially responsible for heading Siegfried's research and development activities. On December 1, 2011, he was appointed Head Strategy and M&A with responsibility for Strategy, Mergers & Acquisitions, Legal & Intellectual Property Management, and Regulatory Affairs. Before joining Siegfried, Wolfgang Wienand held senior management positions at Evonik Industries AG, mainly in the fields of fine chemicals and custom manufacturing for the pharmaceutical industry; latterly, he was responsible for the strategy and business development of Evonik's advanced silanes business with the photovoltaic and semi-conductor industries.
Peter Gehler, Chief Communications Officer
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16
Arnoud Middel, Head Human Resources Global
Tel. +41 62 746 11 50
Siegfried Holding AG
Untere Bruehlstrasse 4
Tel. +41 62 746 11 11
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2016, Siegfried reported annual sales of CHF 718 million and employs at the time being approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.